Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
GlaxoSmithKline
National Cancer Institute (NCI)
Artios Pharma Ltd
Incyte Corporation
Eli Lilly and Company
City of Hope Medical Center
National Cancer Institute (NCI)
OHSU Knight Cancer Institute
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Incyte Corporation
Sutro Biopharma, Inc.
Mural Oncology, Inc
Merck Sharp & Dohme LLC
Toray Industries, Inc
Yonsei University
Universitaire Ziekenhuizen KU Leuven
The University of Hong Kong
NGM Biopharmaceuticals, Inc
National Cancer Institute (NCI)
Cyteir Therapeutics, Inc.
Mayo Clinic
Eli Lilly and Company
Grupo Español de Investigación en Cáncer de Ovario
Astex Pharmaceuticals, Inc.
Kyowa Kirin Co., Ltd.
City of Hope Medical Center
CureLab Oncology
Eastern Cooperative Oncology Group
Eisai Inc.
pharmaand GmbH
National Cancer Institute, Naples
Northwestern University
Cedars-Sinai Medical Center
AGO Research GmbH
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Sotio Biotech Inc.
University of Virginia
AB Science
Barbara Ann Karmanos Cancer Institute
AstraZeneca
University of Maryland, Baltimore
GOG Foundation
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Sotio Biotech Inc.